Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Lin Website

Pengnian Charles Lin, Ph.D.

Portait Photo of Pengnian Charles Lin
Mouse Cancer Genetics Program
Head, Vascular Biology Section
Senior Investigator
Center for Cancer Research
National Cancer Institute
Building 560, Room 12-89
P.O. Box B
Frederick, MD 21702-1201
Phone:  
301-228-4688
Fax:  
301-846-7017
E-Mail:  
linp3@mail.nih.gov

Biography

Dr. P. Charles Lin received his Ph.D. in Cell and Molecular Biology (1988) at the Peking Union Medical College, Institute of Chinese Medical Sciences, Beijing, China. In 1992, he joined the Department of Medicine, Duke University Medical Center as a Research Associate. In 1999, Dr. Lin was appointed Assistant Professor at Vanderbilt University Medical Center. In 2005, he became Associate Professor with Tenure at the Department of Radiation Oncology, Department of Cancer Biology, and Department of Cell & Development Biology at Vanderbilt University School of Medicine.
Dr. Lin established the Vascular Biology Section with the MCGP at the Center for Cancer Research in August, 2010.

Research

The Vascular Biology Section is headed by Dr. P. Charles Lin who joined the MCGP in August, 2010. Vascular biology plays a vital role in the progression of many debilitating diseases including: cancer, diabetes, and heart disease. Vascular disease is the most common cause of death and disability in Western societies. Understanding the vascular system is critical in the war against these diseases. Research in Dr. Lin's laboratory centers on the mechanisms that govern blood vessel formation (angiogenesis) and vascular homeostasis in cancer. Vascular networks form to satisfy the metabolic demands of tissue growth during development. When we reach adulthood, the vascular endothelium becomes quiescent. However, under disease conditions, this delicate balance is disturbed and endothelium is reactivated. What distinguishes physiological angiogenesis during normal growth from pathological angiogenesis in diseases is an important question, which has major implications in therapeutic interventions. Dr. Lin's group believes the major difference is inflammation. Their working hypothesis is that tissue injury/insult leads to inflammation, which then triggers pathological angiogenesis. To this end, they are focusing on the interaction between inflammation and pathological angiogenesis, which offer the potential to preferentially target angiogenesis in disease conditions and spare normal blood vessels. Dr. Lin's group combines genetic and biochemical approaches, in vitro, three-dimensional organotypic culture and animal models as well as non-invasive imaging technology, to dissect the molecular mechanism in angiogenesis and vascular homeostasis in cancer. The current research focuses on three areas: 1). Role of myeloid suppresser cells in regulation of the tumor microenvironment with a focus on angiogenesis and lymphangiogenesis. 2). Vascular integrity and endothelial-to-mesenchymal transformation (EMT) in tumor progression. 3. Exploring the genetic differences in vasculature between human and other species.

This page was last updated on 6/7/2013.